Fibromuscular dysplasia (FMD) mainly affects renal arteries. Percutaneous transluminal renal angioplasty (PTRA) and surgery are effective treatments, but longtime follow-up is lacking. Retrospective follow-up for 7.074.7 years of 69 consecutive patients (age 44713 years) treated for hypertension due to FMD, 59 patients underwent PTRA and eight patients surgery. In two patients no PTRA was performed. Technical success was achieved in 56 (95%) patients undergoing PTRA and all eight undergoing surgery. After successful PTRA, both systolic and diastolic blood pressures (SBP and DBP) had decreased at discharge (from 174733/ 100713 to 138719/80715 mmHg; Po0.0001), and remained lower at 1 month, 1 year, and last follow-up after 7.074.7 years (140725/83712 mmHg; Po0.0001). Serum-creatinine had decreased both at 1 year (from 84728 to 75713 lmol/l; P ¼ 0.0030) and last follow-up (75716 lmol/l; P ¼ 0.0017). The number of antihypertensive drugs decreased (from 2.371.2 before PTRA to 1.471.3 at discharge and at 1 month; Po0.0001, and 1.671.5 at last follow-up; P ¼ 0.0011). SBP decreased more after PTRA among patients with FMD only in the main renal artery than in those with branch artery involvement (43729 vs 20741 mmHg; P ¼ 0.0198). Beneficial effects on BP, creatinine and antihypertensive drugs also occurred after surgery. Patients on antihypertensive drugs at last follow-up had longer hypertension duration before PTRA than those without (5.977.7 vs 1.874.1 years; P ¼ 0.0349). Cure was achieved in 16 (24%), improvement in another 26(39%), and benefit in 42(63%). In conclusion, renal artery FMD, PTRA and surgery have beneficial long-term effects, negatively affected by hypertension duration and branch artery involvement.
Introduction
Fibromuscular dysplasia (FMD) is an uncommon nonatherosclerotic and noninflammatory disease of the arterial system mainly affecting the renal arteries, 1 first described by Leadbetter and Burkland 2 in 1938. The disease is reported to be 10 times more common in females and to appear most in the third and fourth decades of life. 3 The 'gold standard' for the diagnosis of renal artery FMD is the classically abnormal renal arteriogram or a pathologic specimen. 4 When affecting the renal arteries, the FMD changes might lead to renovascular hypertension. 5 Gruntzig et al 6 demonstrated in 1974 that percutaneous transluminal renal angioplasty (PTRA) was highly effective in treating FMD in the renal arteries. FMD, therefore, represents the most common curable form of hypertension. 3 At our institution, surgical revascularisation was the dominant treatment modality for renovascular hypertension in FMD patients until the beginning of the 1990s. Thereafter, PTRA successively became the treatment of choice for renovascular hypertension due to FMD. Angioplasty is known to be effective for the treatment of main renal artery disease; however, nowadays with smaller improved balloons and better catheter techniques, PTRA is the treatment modality of choice in most FMD patients who are symptomatic.
A summary of previous studies of PTRA effects in FMD was recently published. 1 Previous retrospective studies of materials with only FMD as cause of renal artery stenosis have followed patients for a maximum of 48 months, 1, 7 however, whereas follow-up of mean 11.3 years has recently been reported in a mixed material of patients with renal artery stenosis due to either atherosclerosis or fibromuscular dysplasia. 8 Our institution has the responsibility for the treatment of renovascular hypertension in the southernmost health region of Sweden (1.6 million inhabitants), and we now aim to analyse retrospectively long-time effects upon blood pressure (BP), renal function, and antihypertensive treatment in consecutive patients undergoing endovascular and surgical revascularisation of renal artery stenosis caused by FMD, and to identify factors that influence the efficacy of treatment.
Materials and methods
Between 1987 and November 2004, 69 patients (mean age 44713 years, 57 women) were consecutively treated at Malmö University Hospital for renovascular hypertension caused by FMD. A total of 59 patients underwent PTRA and eight patients surgical reconstructions. All surgical reconstructions were performed prior to 1992. In two patients no PTRA was performed due to a low medial pressure gradient found at angiography.
The diagnosis of FMD was established by retrospective study of renal angiography films, and was based on established criteria 9 and the absence of atherosclerotic changes in the aorta and other large arteries. In seven cases, where the angiographic films were not available at follow-up, the diagnosis of FMD was established on the basis of reports from the radiologist and the operating surgeon. Two cases were confirmed by specimen examination. Renal length, the side and length of the FMD changes, involvement of branch arteries, appearance of the FMD lesion (beads, concentric, aneurysmatic changes 10 ) and extrarenal FMD changes were assessed. Reference values for serum (s)-creatinine were 51-105 mmol/l. Patients with s-creatinine X130 mmol/l underwent CO 2 -angiography. PTRA was performed if the pressure gradient at angiography was X10 mmHg. Balloon diameter at PTRA was 5.770.9 mm. Five patients treated by PTRA got stents (one was included in a scientific study of renal artery stenting, one had an aneurysm of the renal artery, and in the other three the remaining medial pressure gradient was X10 mmHg in spite of repeated PTRA attempts). No routine control angiographies were performed.
Follow-up
We retrospectively registered systolic and diastolic blood pressures (SBP and DBP), s-creatinine, and the number of antihypertensive drugs used before revascularisation, at discharge, after 1 year and at the last follow-up after mean 7.074.7 years from patient files at Malmö University Hospital and other referring hospitals in the region. Owing to their effects upon BP, diuretics and nitrates were defined as antihypertensive drugs, even though they may have primarily been given for other reasons. BMI, smoking habits, duration of hypertension prior to treatment, and the presence of diabetes mellitus were recorded. Coronary, cerebral, and peripheral vascular disease was also evaluated. Information about mortality and causes of death was obtained through the death registry of the Swedish Board of Health and Welfare. The ethics committee of the University of Lund approved the study.
Cure, improvement, technical success, and failure Cure was defined as in the Guidelines for the Reporting of Renal Artery Revascularisation in Clinical Trials 11 as DBPo90 mmHg and SBPo140 mmHg off antihypertensive medication. Improvement was defined as DBPo90 mmHg and/or SBPo140 mmHg on the same or reduced number of medications, or a reduction in DBP of at least 15 mmHg with the same or reduced number of medications. Benefit was defined as cure or improvement. 11 Technical success was defined as successful dilatation of the stenotic artery and completion of the process, whereas technical failure was defined as either failure to dilate the stenotic artery, or a major complication such as dissection or perforation during the PTRA procedure.
Statistics
Differences between groups were evaluated with the Mann-Whitney U-test, and differences over time within a group with the Wilcoxon signed rank test. Kaplan-Meier curves were calculated in the survival statistics. Tests were two-tailed and P-valueso0.05 were considered significant. Results are presented as mean7s.d. StatView 4.5 (SAS Institute, Cary, NC, USA) was used for the statistical calculations.
Results
Patient characteristics are given in Table 1 . Rightsided renal artery stenosis occurred in 45 (67%), left-sided stenosis in 9 (13%), and bilateral stenosis in 13 (19%) . The length of the FMD changes was 2.571.4 cm. Technical success was achieved in all patients treated with surgery and 56/59 (95%) patients undergoing PTRA. In 3/59 (5%) PTRA patients, the revascularisation attempt was a failure. All failures occurred before 1992.
Patients undergoing successful PTRA
In the 56 patients undergoing successful PTRA, both SBP and DBP had decreased already at discharge (from 174733/100713 to 138719/80715 mmHg; Po0.0001 for both), and remained lower both after 1 month (142727/85712 mmHg; Po0.0001 for both), after 1 year (143724/84712 mmHg; Po0.0001 for both), and at last follow-up after 7.074.7 (median 7) years (140725/83712 mmHg; Po0.0001 for both, Table 2 ). s-creatinine also had decreased after 1 year (from 84728 mmol/l to 75713 mmol/l; P ¼ 0.0030), and at last follow-up (75716 mmol/l; P ¼ 0.0017, Table 2 ). Furthermore, the number of antihypertensive drugs also decreased (from 2.371.2 before PTRA to 1.471.3 at discharge and after 1 month; Po0.0001, 1.671.3 after 1 year; P ¼ 0.0002, and 1.671.5 at last follow-up; P ¼ 0.0011, Table 2 ). The response in SBP after PTRA was significantly better in patients with FMD affecting only the main renal artery than in those with involvement of branch arteries (43729 vs 20741 mmHg; P ¼ 0.0198, Table 3).
Patients undergoing unsuccessful PTRA
Among the three subjects undergoing unsuccessful PTRA, open revascularisation was performed later with good results in one. In no patient did nephrectomy or dialysis become necessary.
Patients undergoing surgical revascularisation
Significant beneficial effects upon SBP and DBP (181722/10578 mmHg before treatment and Diabetes mellitus (n (%)) 1 (1) 0 (0) 1 (12) In two patients no intervention was performed, and in three patients the PTRA attempt was a failure. (Table 2 ).
All patients (Figure 1 )
At last follow-up after 7.074.7 years, cure as defined in the Guidelines for the Reporting of Renal Artery Revascularisation in Clinical Trials 10 was achieved in 16 (24%) of patients, and improvement in another 26 (39%) of patients. Benefit was thus achieved in 42 (63%) of patients. Patents who were still on antihypertensive medication at last followup had a longer duration of hypertension before treatment (5.
Of the 57 women, nine (16%) reported a previous diagnosis of hypertension during pregnancy and another six (11%) had previously received hormonal contraceptive therapies. Seven patients (six women) suffered from migraine. In all 42 (61%) of patients were current or exsmokers.
Seven patients (10%) had concomitant FMD changes observed in one or more extrarenal vessels, four in iliac arteries, two in mesenteric arteries, two in precerebral arteries, and one in the subclavian artery.
Complications, re-dos, and mortality (Tables 4, 5)
The rate of complications tended to be low in the recent years, and no technical failures of PTRA were reported after 1992. All major procedural PTRA complications such as perforation or dissection of the main renal artery requiring surgery occurred before 1994, whereas peripheral renal infarction (n ¼ 5) occurred throughout the study period (Table  4 ). In no patient did nephrectomy become necessary.
The primary 12-month patency rate was 73% in PTRA patients and 100% in surgically revascularised patients. Of the patients, 19 who were (34%) treated with PTRA needed at least one re-do ( Figure 2 ). In all, 12 of these re-dos were performed within 1 year, 11 within 6 months. In 7/12 cases needing a re-do within 1 year, restenosis was detected because of increasing BP or need of medication, whereas five patients underwent a planned re-do because of a remaining pressure gradient after the first PTRA. No re-dos were necessary among surgically treated patients. Table 5 .
Discussion
The most common clinical manifestation of FMD in renal arteries is hypertension, and revascularisation is indicated when hypertension is poorly controlled or as an alternative to lifelong medication. This retrospective long-term follow-up of 69 consecutive patients with renal artery stenosis due to FMD confirmed that both PTRA and surgical revascularisation are successful techniques for treating renovascular hypertension in FMD. 1, 12 Not only SBP and DBP, but also s-creatinine and the number of antihypertensive drugs decreased significantly already at discharge and remained lower throughout the follow-up of in average 7 years. Comparison with other published series is difficult, however, because of a large variation of selection criteria and length of follow-up in different studies. 1 Previous studies have shown a 43-63% cure rate, improved BP control in 30-50% of patients, and a failure rate of less than 10%. 13, 14 In a meta-analysis of studies with mean follow-up of 11-26 months presented by Ramsay and Waller, 15 the overall cure rate in FMD patients was 50%. In Birrer's et al's 12 study, 74% (20/27) of patients were improved or cured from arterial hypertension after 12 months of follow-up. In this context, it has to be remembered that previous studies often have featured a short follow-up time. Furthermore, cure, improvement, and benefit have not always been defined according to current guidelines, 11 and it has not always been clarified whether diuretics and nitrates were considered as BP lowering drugs. Our long follow-up and wide definition of BP lowering drugs are, therefore, important to bear in mind when comparing our data with previously presented results.
We also confirm that PTRA and surgical revascularisation provide comparable long-term results in the management of RAS due to FMD. 16, 17 Surgical revascularisation is currently reserved for patients who require treatment of other vascular diseases at the same time, or when major PTRA complications 
Minor that cannot be handled with endovascular techniques occur, such as perforation or dissection. In our study, the effects upon BP, s-creatinine and the number of antihypertensive drugs did not differ between patients treated with PTRA and surgical revascularisation. The effects were more clearly significant in the PTRA group, however, due to the larger number of patients in this group. Data with regard to renal function in patients with FMD are limited, 15, 18, 19 but FMD is progressive and might result in deterioration of renal function, although not as often as in patients with atherosclerotic renal artery stenosis. 20 In our study there were seven patients with s-creatinine X115 mmol/1 before PTRA. s-creatinine stabilised or improved in all of these, and also declined significantly in the whole cohort. This is in contrast to our findings in patients with atherosclerotic renal artery stenosis 21 and occlusion, 22 in which s-creatinine levels were unchanged during followup.
FMD is a pathologic diagnosis, 4 but the characteristic changes seen on an angiogram can be used to make the diagnosis, as in previous studies. 9, 23 In our study, we only have two cases with specimen diagnosis. Angiography remains the gold standard for diagnosis and is especially useful in the evaluation of branch vessel disease. Sometimes it is difficult to distinguish FMD from vasculitis, however, and in those cases intravascular ultrasound may be helpful. 24 This method requires further evaluation, however. Furthermore, no subjects in our study showed concomitant signs of vasculitis at diagnosis, and in no subject was vasculitis diagnosed during long time follow-up.
A limitation of our study was the absence of routine angiographic control after revascularisation. This was performed only in cases of recurrent arterial hypertension, a strong indicator of restenosis. 25 The fact that BP values were collected retrospectively from patient files is another limitation of our study which might have lead to an overestimation of benefits.
Indications to stent FMD lesions were persistent pressure gradients after repeated angioplasty attempts or aneurysms in the renal artery. The predictive value of the medial pressure gradient both before and after treatment for the long-term effects of PTRA is currently evaluated at our institution in a study of a larger patient material with atherosclerotic renal artery stenosis.
Angioplasty is effective for the treatment of FMD in the main renal arteries. However, nowadays with smaller balloons and better catheter techniques, PTRA might be used even when branch arteries are affected. The presence of intraparenchymal changes 26, 27 has been proposed as a cause of restenosis and a limited effect of PTRA. This was confirmed in our study, as patients with involvement of branches of the renal artery showed a less pronounced BP response to PTRA. The higher prevalence of FMD among women implies that hormonal factors are important. 28 Furthermore, out of the 57 women in our study 9 (16%) had a previous diagnosis of hypertension in pregnancy, a condition occurring in 4-5% of pregnancies in our region. 29 These observations are in line with the theory about hormonal involvement in FMD pathogenesis, 28 which ought to be investigated further. In our study, the right renal artery was more commonly affected by FMD than the left, as previously shown. 4 As cigarette smoking may be a risk factor for FMD, 30 it is interesting to note that over half of our patients were smokers. This is a considerably higher figure than smoking rates in our region, which in 2000 were 18% for men and 20% for women 18-80 years of age. 31 Restenosis is a relevant problem after PTRA of FMD, as reflected by our frequency of re-dos of 34%. Plouin et al 32 and Baumgartner et al 33 reported no significant difference in the restenosis rate between nonostial atheromatous and FMD renal artery stenosis. In our material, the majority of re-dos were performed within 6 months after PTRA and many were due to suboptimal results of the initial PTRA. Patients treated with PTRA with initial inadequate outcome and those with recurrence or worsening of hypertension should undergo ultrasonographic imaging.
Complications occurred infrequently in our material, especially during the later part of the study period, and included mainly vessel dissection, perforation, and groin haematoma. The persistent occurrence of peripheral renal infarction throughout the study period despite improving the PTRA technique may raise the question of need of distal filter protection as recently suggested by Dorros et al. 34 In summary (Table 6) , we confirm that both PTRA and open surgical revascularisation are successful techniques for treating renovascular hypertension due to FMD. A longer duration of hypertension, higher age and involvement of branch arteries negatively affects, prognosis. The majority of restenoses are identified by increasing BP during the first 6 months after treatment. Table 6 What is already known on this topic Renal artery stenosis (RAS), because of fibromuscular dysplasia (FMD), is a rare cause of arterial hypertension. Both open surgical revascularisation and percutaneous transluminal renal angioplasty are effective in treating RAS caused by FMD.
What this study adds
The long-time efficacy of the above-mentioned treatment modalities is confirmed. Long duration of hypertension, high age and FMD involvement of branch arteries negatively affect efficacy of treatment.
